2016 Press Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
12/08/16MyoKardia to Present at 2016 BMO Capital Markets Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Dec. 08, 2016 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that Tassos Gianakakos, chief executive officer, will present at the BMO Capital Markets Prescription for Success Healthcare Conference on Wednesday, December 14, at 9:20 AM Eastern Time, in New York. In addition, Mr. Gianakakos will participate... 
12/02/16MyoKardia Announces Receipt of Milestone Payment from Sanofi for DCM Candidate MYK-491
$25 Million Milestone Reflects Continued Momentum in Ongoing Collaboration Phase 1 Clinical Trial Planned for First Half of 2017 SOUTH SAN FRANCISCO, Calif., Dec. 02, 2016 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, announced today that the Company has received a $25 million milestone payment in accordance with the research agreement between MyoKa... 
12/01/16MyoKardia Announces Appointment of Marc Semigran, M.D., as Chief Medical Officer
Former Medical Director of the Heart Failure and Cardiac Transplant Program at Massachusetts General Hospital to Lead Clinical Development SOUTH SAN FRANCISCO, Calif., Dec. 01, 2016 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that Marc Semigran, M.D., has joined the Company as chief medical officer. In his new position, Dr. Semigran... 
11/11/16MyoKardia Announces Exploratory Digital Health Substudy as Part of PIONEER-HCM Trial of MYK-461 in Symptomatic, Obstructive Hypertrophic Cardiomyopathy Patients
Trial to Assess Potential Effects of MYK-461 Treatment on Arterial Pulse Wave Morphology as Measured by Investigational Optical Biosensor Wristband SOUTH SAN FRANCISCO, Calif., Nov. 11, 2016 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced an exploratory digital health substudy that is under way as part of the Company’s PIONEER-HCM tria... 
11/07/16MyoKardia Reports Progress on Clinical Programs and Third Quarter 2016 Financial Results
Dosing in Phase 2 PIONEER-HCM trial of MYK-461 in Symptomatic, Obstructive Hypertrophic Cardiomyopathy Under Way; Pathway to Registration Outlined               MYK-491 Dilated Cardiomyopathy Candidate Set to Enter Clinic in First Half of 2017 SOUTH SAN FRANCISCO, Calif., Nov. 07, 2016 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the tre... 
11/04/16MyoKardia Announces Presentations at American Heart Association Scientific Sessions 2016
Clinical Data from Phase 1 SAD Trials of MYK-461 in Hypertrophic Cardiomyopathy Patients and Healthy Volunteers New Animal Model Research Advances Understanding of HCM Pathophysiology SOUTH SAN FRANCISCO, Calif., Nov. 04, 2016 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced presentations at American Heart Association (AHA) Scientific... 
11/02/16MyoKardia Announces Dosing of First Patient in Phase 2 PIONEER-HCM Study of MYK-461 in Symptomatic, Obstructive Hypertrophic Cardiomyopathy
         Pilot Study Designed to Enable Progression to Larger Phase 2 Trial to Finalize Dosing and Endpoints Prior to Single Pivotal Study Trial Will Assess 12-week Safety and Tolerability in Outpatient Setting; Topline Data Expected in Second Half of 2017   SOUTH SAN FRANCISCO, Calif., Nov. 02, 2016 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of h... 
10/31/16MyoKardia to Present at Two Upcoming Investor Conferences in November 
SOUTH SAN FRANCISCO, Calif., Oct. 31, 2016 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that Tassos Gianakakos, chief executive officer, will participate in two upcoming investor conferences in November. Following are details for each presentation: 25th Annual Credit Suisse Healthcare Conference, Monday, November 7 at 3:00 PM M... 
10/03/16MyoKardia Announces Closing of Public Offering of Common Stock Including Full Exercise of Option to Purchase Additional Shares
SOUTH SAN FRANCISCO, Calif., Oct. 03, 2016 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced the closing of its previously announced underwritten public offering of 4,370,000 shares of common stock, at the public offering price of $15.00 per share, which included 570,000 shares sold pursuant to the full exercise by the underwriters of thei... 
09/27/16MyoKardia Announces Pricing of Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., Sept. 27, 2016 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced the pricing of an underwritten public offering of 3,800,000 shares of its common stock at a public offering price of $15.00 per share, before underwriting discounts. In addition, the underwriters have a 30-day option to purchase up to an additiona... 
09/26/16MyoKardia Announces Proposed Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., Sept. 26, 2016 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that it has commenced an underwritten public offering of 3,800,000 shares of its common stock. All shares of common stock will be offered by MyoKardia. In addition, MyoKardia expects to grant the underwriters a 30-day option to purchase up to an a... 
09/21/16MyoKardia Outlines Path to Registration for MYK-461 in Symptomatic, Obstructive Hypertrophic Cardiomyopathy Patients and Provides Pipeline and Research Updates at Inaugural R&D Day
Phase 2 PIONEER-HCM Pilot Study of MYK-461 Under Way with Topline Data Expected in Second Half of 2017  Mortality-Based Efficacy Endpoints Not Required for Registration of MYK-461 Obstructive Hypertrophic Cardiomyopathy (oHCM) Program  Phase 1 Program for MYK-491 for Dilated Cardiomyopathy (DCM) Expected to Initiate in First Half of 2017  SOUTH SAN FRANCISCO, Calif., Sept. 21, 2016 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a pre... 
09/14/16MyoKardia to Host R&D Day on September 21
SOUTH SAN FRANCISCO, Calif., Sept. 14, 2016 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, will host a Research and Development (R&D) Day for analysts and investors on Sept. 21, 2016, at 8:30 a.m. ET in New York City. During the R&D day, presentations by members of MyoKardia’s management team and guest speakers will include: MyoKardia V... 
09/01/16MyoKardia to Present at 2016 Wells Fargo Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Sept. 01, 2016 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that Tassos Gianakakos, chief executive officer, will present at the 2016 Wells Fargo Healthcare Conference on Thursday, September 8, 2016, at 2:55 PM Eastern Time. The conference is being held at the Westin Waterfront Hotel in Boston. To acces... 
08/10/16MyoKardia to Present at the 2016 Wedbush PacGrow Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Aug. 10, 2016 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that members of the Company management team will present at the 2016 Wedbush PacGrow Healthcare Conference on Tuesday, August 16, 2016 at 2:30 PM Eastern Time. The conference is being held at Le Parker Meridien Hotel in New York City. Presenting... 
08/09/16MyoKardia Reports Second Quarter 2016 Financial Results and Continued Progress on Clinical Programs
MYK-461 Phase 2 PIONEER-HCM Study to Initiate in Second Half of 2016 Clinical Program Builds on Positive Topline Results from Phase 1 Trials of MYK-461 in HCM MYK-461 Development Program, Product Pipeline and Platform Focus of MyoKardia R&D Day on Sept. 21 in New York SOUTH SAN FRANCISCO, Calif., Aug. 09, 2016 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascula... 
07/14/16SHaRe Registry Data Published in PNAS Demonstrate the Power of Combining Clinical, Genetic and Structural Data to Gain Insight into Hypertrophic Cardiomyopathy
SOUTH SAN FRANCISCO, Calif., July 14, 2016 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced the publication of an article in the Proceedings of the National Academy of Sciences of the United States of America. The article is the first to examine data from SHaRe, or the Sarcomeric Human Cardiomyopathy Registry, and demonstrates the power o... 
07/11/16MyoKardia Announces Topline Clinical Data Supporting Advancement of MYK-461 to Phase 2 PIONEER-HCM Study in Symptomatic, Obstructive Hypertrophic Cardiomyopathy Patients
MYK-461 Data Suggest Favorable Safety Profile Up to 28 Days Dosing in Healthy Volunteers and Reduction in Excess Cardiac Contractility in All HCM Patients Studied Company Plans to Initiate Phase 2 PIONEER-HCM Study in Second Half of 2016 MyoKardia R&D Day Planned for Fall; Abstract Submitted for Presentation at The American Heart Association’s Scientific Sessions 2016 Company to Host Conference Call and Webcast Today at 2:00 PM PT (5:00 PM ET) SOUTH SAN FRANCISCO, Calif., July 11, 2016 ... 
05/16/16MyoKardia to Present at 2016 UBS Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 16, 2016 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that members of the Company management team are scheduled to present at the 2016 UBS Global Healthcare Conference on Monday, May 23, at 4:00 PM Eastern Time. The conference is being held May 23-25 at the Grand Hyatt New York in Manhattan. Present... 
05/12/16MyoKardia Reports First Quarter 2016 Financial Results and Operational Progress
SOUTH SAN FRANCISCO, Calif., May 12, 2016 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today reported business highlights and financial results for the first quarter ended March 31, 2016. “We continue to make important progress in advancing our science and our pipeline while attracting great people, across all levels of our company, to join us in ... 
05/02/16MyoKardia Receives Orphan Drug Designation for MYK-461 for Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
SOUTH SAN FRANCISCO, Calif., May 02, 2016 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted the company Orphan Drug Designation for MYK-461 for treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM), a subset of hypertrophic cardiomyopathy (HCM). MYK-461 is the ... 
04/13/16MyoKardia Names Mary Cranston to Board of Directors
SOUTH SAN FRANCISCO, Calif., April 13, 2016 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced the appointment of Mary Cranston to its board of directors and as chair of the audit committee. Ms. Cranston is a retired senior partner of Pillsbury Winthrop Shaw Pittman LLP, an international law firm. She was formerly chair and chief executive ... 
03/18/16MyoKardia Reports Fourth Quarter and 2015 Financial Results and Key Milestones
- Lead product candidate demonstrates clinical proof of mechanism in hypertrophic cardiomyopathy (HCM) patients; Phase 2 planned for second half of 2016 - Growing evidence in nonclinical studies that MYK-461 reduces left ventricular outflow tract obstruction, an important driver of clinical outcomes - Development candidate identified for dilated cardiomyopathy (DCM) program; Phase 1 planned for first half of 2017 SOUTH SAN FRANCISCO, Calif., March 18, 2016 (GLOBE NEWSWIRE) -- MyoKardia, In... 
03/07/16MyoKardia Names Sunil Agarwal, M.D., to Board of Directors, New VPs Strengthen Research and Development
SOUTH SAN FRANCISCO, Calif., March 07, 2016 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced the addition of Sunil Agarwal, M.D., to its board as an independent director. Dr. Agarwal is executive vice president and chief medical officer at Ultragenyx Pharmaceutical, where he leads the company's clinical development and operations, regu... 
03/01/16MyoKardia to Present at Cowen and Company 36th Annual Health Care Conference
SOUTH SAN FRANCISCO, Calif., March 01, 2016 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that members of the management team are scheduled to present at the Cowen and Company 36th Annual Health Care Conference on Tuesday, March 8, 2016, at 10:40 a.m. EST. The conference is being held March 7-9, 2016, at the Marriott Copley Place in Bo... 
02/23/16MyoKardia Announces Transition of Chief Medical Officer
SOUTH SAN FRANCISCO, Calif., Feb. 23, 2016 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that Jonathan C. Fox, M.D., Ph.D., chief medical officer (CMO), has decided to transition from his current role with MyoKardia by September 30, 2016. At the end of this transition period, he will become an independent, consulting Senior Advisor to ... 
02/04/16MyoKardia Publishes Article in Science Demonstrating That MYK-461 Prevents and Reverses Disease in Genetic Mouse Models of Hypertrophic Cardiomyopathy
Supports Therapeutic Hypothesis Linking Reduction in Sarcomere Power Output to Improvements in Structural Pathology of HCM SOUTH SAN FRANCISCO, Calif., Feb. 04, 2016 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced the publication of an article in the leading medical journal Science. The article demonstrates the ability of MYK-461, the c...